CAR-T-cell therapies

Languages

Service navigation

Search

Contact information

CAR-T-cell therapies

The CAR T cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) are provisionally listed in Appendix 1 of the Health Insurance Benefits Ordinance, and are reimbursed by Swiss mandatory health insurance for the treatment of diffuse large B cell lymphoma (DLBCL; Kymriah® and Yescarta®), B cell acute lymphocytic leukaemia (ALL;  Kymriah®) and primary mediastinal B cell lymphoma (PMBCL; Yescarta®). To inform future reimbursement decision an HTA will be conducted with the aim of evaluating the safety, efficacy/effectiveness, costs, cost-effectiveness and budget impact of tisagenlecleucel and axicabtagene ciloleucel separately in these indications. In addition, ethical, legal, social and organisational issues associated with these therapies will be investigated.

Dokumente

HTA protocol (PDF, 1 MB, 16.06.2023)

Stakeholder feedback on the HTA protocol (PDF, 715 kB, 16.06.2023)

< back to HTA projects

Last modification 16.06.2023

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html